IOVA FY 2013 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$5M

Operating Income

-$23M

Net Income

-$25M

EPS (Diluted)

$-2.60

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$20M

Total Liabilities

$2M

Stockholders' Equity

$18M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$5M	-$6M	+28.1%
Operating Income	-$23M	-$8M	-178.4%
Net Income	-$25M	-$3M	-667.3%